What Happened

Genentech restructured its research and early development group (gRED), leading to layoffs and the departure of Vishva Dixit, a vice president with nearly 30 years of tenure. The company is closing its infectious disease and physiological chemistry units while downsizing other teams.

Who Is Affected

Key departures include Vishva Dixit, Todd McDevitt (head of cell therapy), and Man-Wah Tan (infectious diseases). Teams like early clinical development, development sciences, and translational medicine are also impacted.

Market Impact

• Genentech is focusing investments on core therapeutic areas.
• Opportunities may arise in realigned teams and therapeutic priorities.
• The biotech continues to hire within gRED in the U.S.

What to Watch

Monitor Genentech’s hiring patterns and strategic shifts in therapeutic focus. Sales teams should target remaining teams for opportunities in aligned areas.